デフォルト表紙
市場調査レポート
商品コード
1603590

ラジオセラノスティクス市場レポート:動向、予測、競合分析 (2030年まで)

Radiotheranostic Market Report: Trends, Forecast and Competitive Analysis to 2030


出版日
発行
Lucintel
ページ情報
英文 150 Pages
納期
3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.30円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

ラジオセラノスティクス市場レポート:動向、予測、競合分析 (2030年まで)
出版日: 2024年11月25日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ラジオセラノスティクスの動向と予測

世界のラジオセラノスティクス市場の将来は、腫瘍市場と腫瘍以外の市場に機会があり、有望です。世界のラジオセラノスティクス市場は、2024年から2030年までのCAGRが17.3%で、2030年までに推定55億米ドルに達すると予想されています。この市場の主な促進要因は、がんの有病率の増加、臨床試験件数の増加、精密医療に対する認識と採用の拡大です。

  • Lucintel社は、放射性同位元素のカテゴリーでは、ルテチウム-177製品の入手可能性と採用が増加しているため、予測期間中にルテチウム-177が最も高い成長を遂げると予測しています。
  • 用途別では、腫瘍が引き続き大きなセグメントです。
  • 地域別では、北米が予測期間を通じて最大地域であり続けると思われます。これは、同地域における精密医療への傾斜の高まりとともに、効率的なイメージング技術の採用が増加しているためです。

ラジオセラノスティクス市場の戦略的成長機会

ラジオセラノスティクス市場には、複数の用途に様々な戦略的成長機会が存在します。これらの機会を活用することで、同分野を拡大し、ラジオセラノスティクス治療の影響力を高めることができます。

  • 腫瘍への応用:腫瘍学、特に治療困難ながんに対するラジオセラノスティクス用途の拡大は、医療上のアンメットニーズに対応し、集中的かつ効率的な治療を通じて市場の成長を促すことができます。
  • 心臓病:心筋灌流イメージングなど、循環器領域におけるラジオセラノスティクスソリューションの開発は、新たな市場領域を開拓し、心血管疾患の診断と治療を強化します。
  • 神経症:神経学では、特に神経変性疾患の画像診断と治療に関して、正確な診断と治療の両方を提供するラジオセラノスティクスの成長に大きな可能性があります。
  • 感染症:結核やウイルス感染症などの感染症にラジオセラノスティクスを拡大することで、早期発見を支援し、がんの早期治療を促進することができ、従来の腫瘍学にとどまらない応用範囲を広げることができます。
  • 地方での医療アクセス:移動装置や遠隔医療を利用して、農村部や十分なサービスを受けていない地域にラジオセラノスティクス製品を導入することは、医療格差を是正すると同時に、市場範囲を拡大することになります。

結論として、これらの動向は、さまざまな医療専門分野(特にX線撮影)における技術革新を促進する戦略的成長の展望を示しています。多様な医療ニーズに対応することで、同市場は持続可能な成長を達成し、世界の健康により大きな影響を与えることができます。

ラジオセラノスティクス市場の促進要因・課題

様々な技術的、経済的、規制的要因がラジオセラノスティクス市場に影響を与えています。これらの市場促進要因・課題を理解することは、市場をうまくナビゲートし、持続的な成長を達成するために不可欠です。

ラジオセラノスティクス市場を牽引する要因は以下の通りです:

1.技術の進歩:ラジオセラノスティクスの製造技術、画像診断法、標的治療法などの革新により、その有効性が向上し、市場の拡大を促しています。

2.がん罹患率の上昇:世界のがん患者の増加により、ラジオセラノスティクスのような標的を絞った治療法が求められるようになり、この分野で使用される放射性同位元素の市場が拡大しています。

3.政府の支援:規制上の優遇措置や融資を通じて、核医学や精密腫瘍学の推進に対する政府の援助が増加しており、放射性同位元素産業の成長を後押ししています。

4.医療の世界化:世界の医療協力により、特に発展途上国においてラジオセラノスティクス治療へのアクセスが拡大しています。

5.個別化医療に対する患者の需要:個別化された低侵襲治療に対する患者のニーズの高まりが、オーダーメイドの治療オプションを提供するラジオセラノスティクスの採用を促進しています。

ラジオセラノスティクス市場の課題は以下の通りです:

1.高価な製造コスト:放射性同位元素の製造や放射線腫瘍治療薬の開発には高いコストがかかるため、購入しやすい価格やアクセスが制限され、市場成長の課題となっています。

2.承認における障害:認可や放射性物質の安全な取り扱いに関する厳しい規制要件は、新しい治療法のイントロダクションを遅らせる可能性があります。

3.サプライチェーンの課題:半減期が短く、生産設備が限られているため、供給不足が発生し、治療が受けられなくなる可能性があります。

結論として、ラジオセラノスティクス市場は、高い製造コストや規制上のハードルといった課題に直面しながらも、技術の進歩や個別化医療に対する需要の高まりによって牽引されています。市場関係者が持続的な成長を達成し、患者に革新的な治療を提供するためには、これらの要因をうまく乗り切ることが不可欠です。

目次

第1章 エグゼクティブサマリー

第2章 世界のラジオセラノスティクス市場:市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 市場動向と予測分析 (2018年~2030年)

  • マクロ経済動向 (2018~2023年) と予測 (2024~2030年)
  • 世界のラジオセラノスティクス市場の動向 (2018~2023年) と予測 (2024~2030年)
  • 世界のラジオセラノスティクス市場:放射性同位元素別
    • ヨウ素131 
    • ヨウ素123 
    • ガリウム68 
    • ルテチウム177 
    • Y-90搭載18F
    • その他
  • 世界のラジオセラノスティクス市場:アプローチ別
    • 標的治療
    • 標的診断
  • 世界のラジオセラノスティクス市場:用途別
    • 腫瘍
    • 腫瘍以外

第4章 地域別の市場動向と予測分析 (2018年~2030年)

  • 世界のラジオセラノスティクス市場:地域別
  • 北米のラジオセラノスティクス市場
  • 欧州のラジオセラノスティクス市場
  • アジア太平洋のラジオセラノスティクス市場
  • その他地域のラジオセラノスティクス市場

第5章 競合分析

  • 製品ポートフォリオ分析
  • 運用統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略分析

  • 成長機会分析
    • 世界のラジオセラノスティクス市場の成長機会:放射性同位元素別
    • 世界のラジオセラノスティクス市場の成長機会:アプローチ別
    • 世界のラジオセラノスティクス市場の成長機会:用途別
    • 世界のラジオセラノスティクス市場の成長機会:地域別
  • 世界のラジオセラノスティクス市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界のラジオセラノスティクス市場の生産能力拡大
    • 世界のラジオセラノスティクス市場における企業合併・買収 (M&A)、合弁事業
    • 認証とライセンシング

第7章 主要企業のプロファイル

  • Novartis
  • Bayer
  • Progenics Pharmaceuticals
  • Telix Pharmaceuticals Limited
  • ITM Radiopharma
  • Life Molecular Imaging
  • RadioMedix
目次

Radiotheranostic Trends and Forecast

The future of the global radiotheranostic market looks promising with opportunities in the oncology and non-oncology markets. The global radiotheranostic market is expected to reach an estimated $5.5 billion by 2030 with a CAGR of 17.3% from 2024 to 2030. The major drivers for this market are the increasing prevalence of cancer, the rising number of clinical trials, and the growing awareness and adoption of precision medicines.

  • Lucintel forecasts that, within the radioisotope category, lutetium-177 is expected to witness the highest growth over the forecast period due to the increasing availability and adoption of lu-177 products.
  • Within the application category, oncology will remain the larger segment.
  • In terms of regions, North America will remain the largest region over the forecast period due to the increasing adoption of efficient imaging technologies along with a growing inclination towards precision medicine in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Radiotheranostic Market

Emerging trends in the radiotheranostics market are reshaping its future applications and dynamics:

  • Precision Oncology: One of these trends is precision oncology, which uses radiotheranostics to target cancerous cells specifically, thus sparing healthy tissues from harm. It has become a cornerstone in modern cancer therapy, as it leads to better patient outcomes with fewer side effects.
  • Globalization of Radioisotope Supply: This globalization ensures that the supply chains of radioisotopes are broader, leading to the availability of radiotheranostics therapies from any part of the world. Such efforts help mitigate potential shortages through the diversification of sources, ensuring consistent access to treatments globally.
  • Integration with Digital Health: The introduction of AI and telemedicine among digital health technologies into radiotheranostics allows for better diagnosis and treatment planning. These innovations facilitate real-time monitoring and more accurate dosimetry, resulting in improved therapeutic outcomes.
  • Expansion Beyond Oncology: The use of radiotheranostics has extended beyond oncology into cardiology, neurology, and infectious diseases. This creates new opportunities and expands the reach of these interventions.
  • Patient-Centric Care Models: We are seeing the introduction of patient-centered care models based on personalized treatment plans and a multispecialty approach in the radiotheranostics field. These models are raising patient satisfaction levels and improving adherence to therapeutic protocols, which in turn enhances therapeutic outcomes.

In conclusion, these trends are revolutionizing radiotheranostics and making it a cornerstone of personalized medicine, gradually penetrating diverse fields of medicine.

Recent Developments in the Radiotheranostic Market

The radiotheranostics market is rapidly evolving, with several key developments shaping its growth and impact. These advancements have increased the effectiveness of treatment and expanded access to radiotheranostics therapies.

  • Novel Radiation Theragnostic Agents: The development of new radiation theragnostic agents, specifically for prostate and neuroendocrine tumors, has resulted in more precise treatment and better outcomes for patients.
  • Advanced Manufacturing Techniques: Advanced radioisotope production techniques have increased the availability of critical isotopes, such as Lutetium-177 and Gallium-68, which are used for cancer diagnosis, reducing costs and widening access to these therapies.
  • Regulatory Approvals: Simplified regulatory proceedings in key markets have facilitated faster approval of radiotherapeutics, enabling swift access to novel treatments for patients.
  • Strategic Collaborations: Strategic alliances between pharmaceutical companies, research institutions, and healthcare service providers aim to foster innovation while enhancing the development and delivery of radioactive therapeutics.
  • Global Market Expansion: Growing investment in nuclear medicine infrastructure globally, coupled with the adoption of therapies in emerging markets, has necessitated global growth in radiotheranostics.

In conclusion, these key developments are strongly impacting the radiotheranostics market by fueling innovation, increasing access, and improving patient outcomes. As the market continues to grow, these changes will be instrumental in shaping its future.

Strategic Growth Opportunities for Radiotheranostic Market

A variety of strategic growth opportunities exist within multiple applications across the radiotheranostics market. Tapping into these opportunities can expand the sector and increase the influence of radiotheranostics therapies.

  • Oncology Applications: Expanding radiotherapeutic applications for oncology, especially for hard-to-treat cancers, can address unmet medical needs and stimulate market growth through focused and efficient treatment.
  • Cardiology: The development of radiotheranostics solutions in cardiology, such as for myocardial perfusion imaging, will open up new market areas and enhance the diagnosis and treatment of cardiovascular conditions.
  • Neurology: In neurology, there is great potential for the growth of radiotheranostics, particularly with respect to imaging and treating neurodegenerative diseases, providing both accurate diagnostics and therapy.
  • Infectious Diseases: Expanding radiotheranostics into infectious diseases, such as tuberculosis and viral infections, will assist in early detection and promote early cancer treatment, widening the scope beyond traditional oncology applications.
  • Rural Healthcare Access: The use of mobile units or telemedicine to bring radiotheranostics into rural and underserved areas would reduce healthcare disparities while expanding the market reach.

In conclusion, these trends present strategic growth prospects that are driving innovation within various medical specialties, particularly radiography. By addressing diverse healthcare needs, the market can achieve sustainable growth and have a broader impact on global health.

Radiotheranostic Market Driver and Challenges

Various technological, economic, and regulatory factors affect the radiotheranostics market. Understanding these drivers and challenges is essential for navigating the market successfully and achieving sustainable growth.

The factors responsible for driving the radiotheranostic market include:

1. Technological Advancements: Innovations in radiation therapeutics production techniques, imaging methods, and targeted therapies have enhanced their effectiveness, stimulating market expansion.

2. Rising Cancer Incidence: The global increase in cancer cases demands more target-oriented therapies like radiotherapy, resulting in larger markets for radioisotopes used in this area.

3. Government Support: Increasing government assistance for the promotion of nuclear medicine and precision oncology through regulatory incentives and financing is boosting the growth of the radiotheranostics industry.

4. Globalization of Healthcare: Global healthcare collaborations have opened up access to radiotheranostics therapies, especially in developing nations.

5. Patient Demand for Personalized Medicine: Growing patient demand for personalized, minimally invasive treatments is driving the adoption of radiotheranostics, which offer tailored therapeutic options.

Challenges in the radiotheranostic market include:

1. Expensive Production Costs: The high cost of producing radioisotopes and developing radiotheranostics agents can limit affordability and access, posing a challenge to market growth.

2. Obstacles in Approvals: Stringent regulatory requirements for approval and the safe handling of radioactive materials can delay the introduction of new therapies.

3. Supply Chain Challenges: These include short half-life periods and limited production facilities, creating the potential for shortages and leading to treatment unavailability.

In conclusion, the radiotheranostics market is driven by technological advancements and the rising demand for personalized medicine, while facing challenges such as high production costs and regulatory hurdles. Successfully navigating these factors is essential for market players to achieve sustainable growth and deliver innovative treatments to patients.

List of Radiotheranostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radiotheranostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radiotheranostic companies profiled in this report include-

  • Novartis
  • Bayer
  • Progenics Pharmaceuticals
  • Telix Pharmaceuticals Limited
  • ITM Radiopharma
  • Life Molecular Imaging
  • RadioMedix

Radiotheranostic by Segment

The study includes a forecast for the global radiotheranostic by radioisotope, approach, application, and region.

Radiotheranostic Market by Radioisotope [Analysis by Value from 2018 to 2030]:

  • Iodine-131
  • Iodine-123
  • Gallium-68
  • Lutetium-177
  • 18F With Y-90
  • Others

Radiotheranostic Market by Approach [Analysis by Value from 2018 to 2030]:

  • Targeted Therapeutic
  • Targeted Diagnostic

Radiotheranostic Market by Application [Analysis by Value from 2018 to 2030]:

  • Oncology
  • Non-Oncology

Radiotheranostic Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Radiotheranostic Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are recent developments by major radiotheranostics producers in key regions: the USA, China, India, Japan, and Germany:

  • United States: The FDA has approved several radiotheranostics therapies for prostate cancer and neuroendocrine tumors, among others. This has been made possible by increasing funding in research and academic-industry partnerships that foster the development of next-generation radiotheranostics.
  • China: China's investment in its nuclear medicine infrastructure includes the domestic production of radioisotopes. Recently, the country has established centers for radiotheranostics therapies through collaborations with global firms, meeting the rising demand for precise oncology care delivery.
  • Germany: Institutions like the Deutsches Krebsforschungszentrum (German Cancer Research Center) have taken leadership roles in conducting clinical trials for new agents used in radiotheranostics. The country is also improving its regulatory framework to expedite patient access to modern treatments.
  • India: Government-driven initiatives aimed at enhancing nuclear medicine capabilities are positioning India as a key player in the growing radiotheranostics domain. Recent developments include affordable radiotheranostics solutions and collaborations with overseas partners to boost technical know-how.
  • Japan: Japan has seen progress in radioisotope production and distribution, among other developments, all aimed at integrating radiotheranostics into personalized medicine. Government support for research and the development of novel radiotheranostics agents is driving market growth, particularly in oncology.

Features of the Global Radiotheranostic Market

Market Size Estimates: Radiotheranostic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radiotheranostic market size by radioisotope, approach, application, and region in terms of value ($B).

Regional Analysis: Radiotheranostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different radioisotope, approaches, applications, and regions for the radiotheranostic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radiotheranostic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the radiotheranostic market by radioisotope (iodine-131, iodine-123, gallium-68, lutetium-177, 18F with Y-90, and others), approach (targeted therapeutic and targeted diagnostic), application (oncology and non-oncology), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radiotheranostic Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Radiotheranostic Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Radiotheranostic Market by Radioisotope
    • 3.3.1: Iodine-131
    • 3.3.2: Iodine-123
    • 3.3.3: Gallium-68
    • 3.3.4: Lutetium-177
    • 3.3.5: 18F with Y-90
    • 3.3.6: Others
  • 3.4: Global Radiotheranostic Market by Approach
    • 3.4.1: Targeted Therapeutic
    • 3.4.2: Targeted Diagnostic
  • 3.5: Global Radiotheranostic Market by Application
    • 3.5.1: Oncology
    • 3.5.2: Non-oncology

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Radiotheranostic Market by Region
  • 4.2: North American Radiotheranostic Market
    • 4.2.1: North American Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
    • 4.2.2: North American Market by Application: Oncology and Non-oncology
  • 4.3: European Radiotheranostic Market
    • 4.3.1: European Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
    • 4.3.2: European Market by Application: Oncology and Non-oncology
  • 4.4: APAC Radiotheranostic Market
    • 4.4.1: APAC Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
    • 4.4.2: APAC Market by Application: Oncology and Non-oncology
  • 4.5: ROW Radiotheranostic Market
    • 4.5.1: ROW Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
    • 4.5.2: ROW Market by Application: Oncology and Non-oncology

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Radiotheranostic Market by Radioisotope
    • 6.1.2: Growth Opportunities for the Global Radiotheranostic Market by Approach
    • 6.1.3: Growth Opportunities for the Global Radiotheranostic Market by Application
    • 6.1.4: Growth Opportunities for the Global Radiotheranostic Market by Region
  • 6.2: Emerging Trends in the Global Radiotheranostic Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Radiotheranostic Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radiotheranostic Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Novartis
  • 7.2: Bayer
  • 7.3: Progenics Pharmaceuticals
  • 7.4: Telix Pharmaceuticals Limited
  • 7.5: ITM Radiopharma
  • 7.6: Life Molecular Imaging
  • 7.7: RadioMedix